603127 昭衍新药
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,657,624-17.87%2,376,4872,267,9711,516,6801,075,905
减:营业总成本1,663,215-5.70%1,622,0101,418,7661,086,978804,306
    其中:营业成本1,314,312-9.02%1,363,7011,181,660777,558523,092
               财务费用(66,802)-33.05%(151,091)(154,682)(19,156)2,477
               资产减值损失(156,761)135.59%(31,232)(2,792)(1,331)(1,510)
公允价值变动收益447,560-452.27%(245,642)349,567157,77758,946
投资收益18,014-49.98%9,62813,02217,0001,524
    其中:对联营企业和合营企业的投资收益----(3,069)(2,691)(426)--
营业利润337,991223.91%507,0961,225,639642,889361,118
利润总额337,493224.39%506,9501,240,002642,004360,572
减:所得税费用39,65115.65%115,398166,80285,58746,944
净利润297,843326.98%391,5531,073,200556,416313,628
减:非控股权益1-100.03%(5,440)(1,057)(1,043)(1,386)
股东净利润297,841302.08%396,9931,074,257557,460315,014

市场价值指针
每股收益 (元) *0.400300.00%0.5301.4401.0801.000
每股派息 (元) *0.120300.00%0.1600.4000.3600.350
每股净资产 (元) *11.1083.05%11.04015.27718.7205.390
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容